Cheston J. Larson

Boundless Bio, Inc. (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, has announced the pricing of its initial public offering of 6,250,000 shares of its common stock at an initial public offering price of US$16.00 per share. All of the shares are being offered by Boundless Bio. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be US$100.0 million. Boundless Bio’s common stock is expected to begin trading on the Nasdaq Global Select Market on March 28, 2024, under the ticker symbol “BOLD.” The offering is expected to close on April 2, 2024, subject to the satisfaction of customary closing conditions. In addition, Boundless Bio has granted the underwriters a 30-day option to purchase up to an additional 937,500 shares of common stock at the initial public offering price, less underwriting discounts and commissions. Latham & Watkins LLP is advising Boundless Bio on the offering, with a corporate team led by San Diego partners Matt Bush and Cheston Larson, with associates Nadia Patino, Sterling Swift, and Arielle Schechtman. Advice was also provided on benefits matters by San Diego partner Holly Bauer, with associate Julie Voorhes; on FDA regulatory matters by Bay Area partner Betty Pang and Washington, D.C. counsel Chad Jennings, with San Diego associate Kiera Murphy; and on IP matters by San Diego counsel Darryl Steensma, with associates Robert Yeh and Kristina Funahashi.~~

Mar 28

1 min

Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, has announced the pricing of its upsized initial public offering of 13,920,000 shares of common stock at a price to the public of US$12 per share. All of the shares of common stock are being offered by Artiva. The gross proceeds to Artiva from the offering are expected to be approximately US$167 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Artiva. In addition, Artiva has granted the underwriters a 30-day option to purchase up to an additional 2,088,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions. Latham & Watkins LLP represents the underwriters in the offering, with a capital markets team led by San Diego partners Matt Bush and Cheston Larson, and counsel Anthony Gostanian, with associates Omeed Valipour, Rachel Staub, and Samantha Wang.~~

Jul 19

1 min

Mainstay Medical Holdings plc has announced an equity financing in which it will receive gross proceeds of US$125 million. Mainstay intends to use the funds to support the company’s continued commercial growth of ReActiv8® Restorative Neurostimulation in the US, Europe, and Australia, additional post-market clinical studies and research, and general operations. Latham & Watkins LLP advised Mainstay Medical Holdings in the transaction with a corporate team led by San Diego partners Cheston Larson and Matt Bush, and counsel Evan Youngstrom, with associate Alex Stuart-Lovell.~~

Mar 1

1 min

Iovance Biotherapeutics, Inc. (Nasdaq: IOVA) (Iovance), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte therapies for patients with cancer, has announced the pricing of an underwritten offering of 23,014,000 shares of its common stock at an offering price of US$9.15 per share. The gross proceeds from the offering, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by Iovance, are expected to be approximately US$211 million. The offering is expected to close on or about February 22, 2024, subject to customary closing conditions. Latham & Watkins LLP is advising the underwriters in the offering, with a capital markets team led by San Diego partners Matt Bush and Cheston Larson, and counsel Anthony Gostanian, with associates Peter Simon and Sterling Swift.~~

Feb 20

1 min

Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, has announced the pricing of an underwritten offering of 86,486,486 shares of its common stock at a price of US$1.85 per share. All of the shares to be sold in the offering are to be sold by Erasca. The gross proceeds to Erasca from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be approximately US$160 million. In addition, Erasca has granted the underwriters a 30-day option to purchase up to an additional 12,972,972 shares of common stock at the offering price. The offering is expected to close on May 21, 2024, subject to the satisfaction of customary closing conditions. Latham & Watkins advised Erasca in the offering, with a corporate team led by San Diego partners Cheston Larson and Matt Bush, and counsel Anthony Gostanian, with associates Shelby Harrison and Arielle Schechtman.~~

May 17

1 min